WO1998039450A2 - Oberflächenprotein (spsa-protein) von streptococcus pneumoniae deletierte abkömmlinge, expressionssssystem für diese proteine und vaccine mit den proteinen - Google Patents
Oberflächenprotein (spsa-protein) von streptococcus pneumoniae deletierte abkömmlinge, expressionssssystem für diese proteine und vaccine mit den proteinen Download PDFInfo
- Publication number
- WO1998039450A2 WO1998039450A2 PCT/EP1998/001149 EP9801149W WO9839450A2 WO 1998039450 A2 WO1998039450 A2 WO 1998039450A2 EP 9801149 W EP9801149 W EP 9801149W WO 9839450 A2 WO9839450 A2 WO 9839450A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- secretory
- deleted
- surface protein
- positions
- Prior art date
Links
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims abstract description 55
- 229940031000 streptococcus pneumoniae Drugs 0.000 title claims abstract description 54
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 39
- 102000018697 Membrane Proteins Human genes 0.000 title claims abstract description 36
- 108010052285 Membrane Proteins Proteins 0.000 title claims abstract description 36
- 229960005486 vaccine Drugs 0.000 title claims abstract description 11
- 230000014509 gene expression Effects 0.000 title claims abstract description 8
- 230000003248 secreting effect Effects 0.000 claims description 36
- 101150063569 slgA gene Proteins 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 102000040739 Secretory proteins Human genes 0.000 claims description 15
- 108091058545 Secretory proteins Proteins 0.000 claims description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 102000014914 Carrier Proteins Human genes 0.000 claims description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 241000194017 Streptococcus Species 0.000 claims description 5
- 108091008324 binding proteins Proteins 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 108010040473 pneumococcal surface protein A Proteins 0.000 description 18
- 101150037205 spsA gene Proteins 0.000 description 14
- 150000004676 glycans Chemical class 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 101710183389 Pneumolysin Proteins 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 238000010367 cloning Methods 0.000 description 8
- 210000002919 epithelial cell Anatomy 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 102220472274 Eukaryotic translation initiation factor 4E transporter_R36A_mutation Human genes 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 101150080370 pspA gene Proteins 0.000 description 6
- 102000028556 IgA binding proteins Human genes 0.000 description 5
- 108091009322 IgA binding proteins Proteins 0.000 description 5
- 108090000301 Membrane transport proteins Proteins 0.000 description 5
- 102000003939 Membrane transport proteins Human genes 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102400001107 Secretory component Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 206010033078 Otitis media Diseases 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 229940099472 immunoglobulin a Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 2
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 2
- 101710087657 Manganese ABC transporter substrate-binding lipoprotein Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 208000035109 Pneumococcal Infections Diseases 0.000 description 2
- 108010046644 Polymeric Immunoglobulin Receptors Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 101100130893 Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) mntA gene Proteins 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241001301450 Crocidium multicaule Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100084597 Dictyostelium discoideum pspA gene Proteins 0.000 description 1
- 241001596967 Escherichia coli M15 Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010058859 Pneumococcal bacteraemia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102100035187 Polymeric immunoglobulin receptor Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 description 1
- 240000003801 Sigesbeckia orientalis Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 101900032831 Streptococcus pneumoniae Pneumolysin Proteins 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 229940052778 neisseria meningitidis Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940124733 pneumococcal vaccine Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 101150043479 psaA gene Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940030998 streptococcus agalactiae Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53813798A JP2001524073A (ja) | 1997-03-03 | 1998-03-02 | 肺炎連鎖球菌の新規の表面タンパク質(SpsA−タンパク質)、欠失した誘導体、該タンパク質用の発現システム及び該タンパク質を含むワクチン |
EP98916880A EP0991762A2 (de) | 1997-03-03 | 1998-03-02 | OBERFLÄCHENPROTEIN (SPSA-PROTEIN) VON $i(STREPTOCOCCUS PNEUMONIAE) DELIERTE ABKÖMMLINGE, EXPRESSIONSSSYSTEM FÜR DIESE PROTEINE UND VACCINE MIT DEN PROTEINEN |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19708537.7 | 1997-03-03 | ||
DE19708537A DE19708537A1 (de) | 1997-03-03 | 1997-03-03 | Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998039450A2 true WO1998039450A2 (de) | 1998-09-11 |
WO1998039450A3 WO1998039450A3 (de) | 1998-11-05 |
Family
ID=7822047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/001149 WO1998039450A2 (de) | 1997-03-03 | 1998-03-02 | Oberflächenprotein (spsa-protein) von streptococcus pneumoniae deletierte abkömmlinge, expressionssssystem für diese proteine und vaccine mit den proteinen |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0991762A2 (de) |
JP (1) | JP2001524073A (de) |
DE (1) | DE19708537A1 (de) |
WO (1) | WO1998039450A2 (de) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0846766A2 (de) * | 1996-09-24 | 1998-06-10 | Smithkline Beecham Corporation | IgA Fc-bindendes Protein von Streptococcus pneumoniae |
WO2002008426A2 (en) * | 2000-07-20 | 2002-01-31 | Hansa Medical Ab | Fh-binding protein of streptococcus pneumoniae |
US6503511B1 (en) | 1998-04-07 | 2003-01-07 | Medimmune, Inc. | Derivatives of choline binding proteins for vaccines |
WO2007071711A2 (en) | 2005-12-22 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Vaccine |
WO2007116028A2 (en) | 2006-04-07 | 2007-10-18 | Glaxosmithkline Biologicals S.A. | Conjugate vaccines |
WO2009000826A1 (en) | 2007-06-26 | 2008-12-31 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
EP2140878A1 (de) | 2000-09-15 | 2010-01-06 | GlaxoSmithKline Biologicals S.A. | Impfstoff gegen Streptococcus Pneumoniae |
EP2364724A1 (de) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Impfstoffzusammensetzungen mit einem Saponin-Adjuvans |
WO2011110241A1 (en) | 2010-03-09 | 2011-09-15 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising s. pneumoniae polysaccharides conjugated to carrier proteins |
WO2012156391A1 (en) | 2011-05-17 | 2012-11-22 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
EP2612680A1 (de) | 2008-04-16 | 2013-07-10 | GlaxoSmithKline Biologicals SA | Impfstoff |
WO2017067962A1 (en) | 2015-10-21 | 2017-04-27 | Glaxosmithkline Biologicals S.A. | Vaccine |
US9714283B2 (en) | 2014-10-28 | 2017-07-25 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
AU2027400A (en) * | 1998-11-19 | 2000-06-05 | St. Jude Children's Research Hospital | Identification and characterization of novel pneumococcal choline binding proteins, cbpg and cbpd, and diagnostic and therapeutic uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039113A2 (en) * | 1995-06-02 | 1996-12-12 | Uab Research Foundation | Oral administration of pneumococcal antigens |
WO1997041151A2 (en) * | 1996-05-01 | 1997-11-06 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
WO1998018930A2 (en) * | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
WO1998021337A2 (en) * | 1996-11-12 | 1998-05-22 | Regents Of The University Of Minnesota | C3 BINDING PROTEIN OF $i(STREPTOCOCCUS PNEUMONIAE) |
-
1997
- 1997-03-03 DE DE19708537A patent/DE19708537A1/de not_active Withdrawn
-
1998
- 1998-03-02 JP JP53813798A patent/JP2001524073A/ja active Pending
- 1998-03-02 EP EP98916880A patent/EP0991762A2/de not_active Withdrawn
- 1998-03-02 WO PCT/EP1998/001149 patent/WO1998039450A2/de not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039113A2 (en) * | 1995-06-02 | 1996-12-12 | Uab Research Foundation | Oral administration of pneumococcal antigens |
WO1997041151A2 (en) * | 1996-05-01 | 1997-11-06 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
WO1998018930A2 (en) * | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
WO1998021337A2 (en) * | 1996-11-12 | 1998-05-22 | Regents Of The University Of Minnesota | C3 BINDING PROTEIN OF $i(STREPTOCOCCUS PNEUMONIAE) |
Non-Patent Citations (1)
Title |
---|
HAMMERSCHMIDT S ET AL.: "SpsA, a novel pnemumococcal surface protein with specific binding to secretory immunoglobulin a and secretroy component" MOLECULAR MICROBIOLOGY, Bd. 25, Nr. 6, September 1997, Seiten 1113-1124, XP002075556 * |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0846766A2 (de) * | 1996-09-24 | 1998-06-10 | Smithkline Beecham Corporation | IgA Fc-bindendes Protein von Streptococcus pneumoniae |
EP0846766A3 (de) * | 1996-09-24 | 1999-11-24 | Smithkline Beecham Corporation | IgA Fc-bindendes Protein von Streptococcus pneumoniae |
US6503511B1 (en) | 1998-04-07 | 2003-01-07 | Medimmune, Inc. | Derivatives of choline binding proteins for vaccines |
US7435421B2 (en) | 1998-04-07 | 2008-10-14 | Medimmune, Inc. | Derivatives of choline binding proteins for vaccines |
WO2002008426A2 (en) * | 2000-07-20 | 2002-01-31 | Hansa Medical Ab | Fh-binding protein of streptococcus pneumoniae |
WO2002008426A3 (en) * | 2000-07-20 | 2002-05-30 | Hansa Medical Ab | Fh-binding protein of streptococcus pneumoniae |
EP2305298A1 (de) | 2000-09-15 | 2011-04-06 | GlaxoSmithKline Biologicals s.a. | Impfstoff gegen Streptococcus Pneumoniae |
EP2140878A1 (de) | 2000-09-15 | 2010-01-06 | GlaxoSmithKline Biologicals S.A. | Impfstoff gegen Streptococcus Pneumoniae |
EP2305297A1 (de) | 2000-09-15 | 2011-04-06 | GlaxoSmithKline Biologicals s.a. | Impfstoff gegen Streptococcus Pneumoniae |
EP2314313A1 (de) | 2000-09-15 | 2011-04-27 | GlaxoSmithKline Biologicals S.A. | Impfstoff gegen Streptococcus Pneumoniae |
US10039823B2 (en) | 2005-12-13 | 2018-08-07 | Glaxosmithkline Biologicals, S.A. | Vaccine compositions comprising a saponin adjuvant |
EP2364721A1 (de) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Impfstoffzusammensetzungen mit einem Saponin-Adjuvans |
US10143745B2 (en) | 2005-12-13 | 2018-12-04 | GlacoSmithKline Biologicals, S.A. | Vaccine compositions comprising a saponin adjuvant |
EP2364722A1 (de) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Impfstoffzusammensetzungen mit einem Saponin-adjuvans |
EP2364723A1 (de) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Impfstoffzusammensetzungen mit einem Saponin-Adjuvans |
EP2364724A1 (de) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Impfstoffzusammensetzungen mit einem Saponin-Adjuvans |
EP2364720A1 (de) | 2005-12-13 | 2011-09-14 | GlaxoSmithKline Biologicals S.A. | Impfstoffzusammensetzungen mit einem saponin-adjuvans |
WO2007071707A2 (en) | 2005-12-22 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Pneumococcal polysaccharide conjugate vaccine |
WO2007071710A2 (en) | 2005-12-22 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
EP2382986A2 (de) | 2005-12-22 | 2011-11-02 | GlaxoSmithKline Biologicals s.a. | Streptococcus pneumoniae-impfstoff |
EP2384765A2 (de) | 2005-12-22 | 2011-11-09 | GlaxoSmithKline Biologicals S.A. | Streptococcus pneumoniae Vakzine |
EP2402025A2 (de) | 2005-12-22 | 2012-01-04 | GlaxoSmithKline Biologicals S.A. | Impfstoff |
WO2007071711A2 (en) | 2005-12-22 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Vaccine |
EP3020411A1 (de) | 2005-12-22 | 2016-05-18 | GlaxoSmithKline Biologicals s.a. | Impfstoff |
WO2007116028A2 (en) | 2006-04-07 | 2007-10-18 | Glaxosmithkline Biologicals S.A. | Conjugate vaccines |
EP2392346A1 (de) | 2006-04-07 | 2011-12-07 | GlaxoSmithKline Biologicals SA | Streptococcus pneumoniae Impfstoff |
WO2009000826A1 (en) | 2007-06-26 | 2008-12-31 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
EP2687228A2 (de) | 2007-06-26 | 2014-01-22 | GlaxoSmithKline Biologicals S.A. | Impfstoff mit streptococcus pneumoniae-kapsulären polysaccharid-konjugaten |
EP2612680A1 (de) | 2008-04-16 | 2013-07-10 | GlaxoSmithKline Biologicals SA | Impfstoff |
WO2011110241A1 (en) | 2010-03-09 | 2011-09-15 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising s. pneumoniae polysaccharides conjugated to carrier proteins |
WO2012156391A1 (en) | 2011-05-17 | 2012-11-22 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
US9714283B2 (en) | 2014-10-28 | 2017-07-25 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US9969793B2 (en) | 2014-10-28 | 2018-05-15 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US10683343B2 (en) | 2014-10-28 | 2020-06-16 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US11339206B2 (en) | 2014-10-28 | 2022-05-24 | Adma Biomanufacturing, Llc | Compositions and methods for the treatment of immunodeficiency |
US11780906B2 (en) | 2014-10-28 | 2023-10-10 | Adma Biomanufacturing, Llc | Compositions and methods for the treatment of immunodeficiency |
WO2017067962A1 (en) | 2015-10-21 | 2017-04-27 | Glaxosmithkline Biologicals S.A. | Vaccine |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
US11084870B2 (en) | 2017-03-15 | 2021-08-10 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
US11897943B2 (en) | 2017-03-15 | 2024-02-13 | Adma Biomanufacturing, Llc | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
Also Published As
Publication number | Publication date |
---|---|
JP2001524073A (ja) | 2001-11-27 |
WO1998039450A3 (de) | 1998-11-05 |
DE19708537A1 (de) | 1998-09-10 |
EP0991762A2 (de) | 2000-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRILES et al. | PspA and PspC: their potential for use as pneumococcal vaccines | |
Hammerschmidt et al. | SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component | |
EP0991762A2 (de) | OBERFLÄCHENPROTEIN (SPSA-PROTEIN) VON $i(STREPTOCOCCUS PNEUMONIAE) DELIERTE ABKÖMMLINGE, EXPRESSIONSSSYSTEM FÜR DIESE PROTEINE UND VACCINE MIT DEN PROTEINEN | |
DE69737125T3 (de) | Streptococcus pneumoniae-Antigene und Impfstoffe | |
Briles et al. | PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice | |
US7820789B2 (en) | Mutant pneumolysin proteins | |
DE69934299T2 (de) | Gruppe b-streptococcus antigene | |
PATON et al. | Molecular analysis of putative pneumococcal virulence proteins | |
Jacobs et al. | Identification, purification, and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis | |
DE60027890T2 (de) | Streptococcus pneumoniae proteine und impfstoffe | |
EP2281891A2 (de) | Antigene aus Streptococcus | |
EP2261358A2 (de) | Streptokokken-Antigene | |
US6426074B1 (en) | Group B Streptococcus vaccine | |
US20120308596A1 (en) | Novel streptococcus antigens | |
Lu et al. | Species-specific interaction of Streptococcus pneumoniae with human complement factor H | |
US20060177465A1 (en) | Streptococcus antigens | |
US20040265933A1 (en) | Proteins | |
JPH0710774A (ja) | スプレプトコッカス・スイス感染に対するワクチン | |
AU776735B2 (en) | Genes and proteins, and their use | |
WO1991004049A1 (en) | CONJUGATE VACCINE FOR GROUP B $i(STREPTOCOCCUS) | |
DE69925866T2 (de) | Aussermembranproteine, ihre gene, und deren verwendung | |
US20030104000A1 (en) | Genes and proteins, and their use | |
AU2008229967B2 (en) | Novel streptococcus antigens | |
EP1950302A2 (de) | Streptokokken-Antigene | |
Roche | Characterization of the protective antibody responses to PSPA in Streptococcus pneumoniae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998916880 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 538137 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998916880 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998916880 Country of ref document: EP |